An inhibitor of CDK4/6 significantly reduced renal injury in a mouse model of ischemia-reperfusion injury. Acute kidney injury (AKI) is a common and costly side effect of chemotherapy characterized by sudden impairment of kidney function. There are currently no approved therapeutics to prevent or treat AKI. CDK4/6 inhibition protects renal cells from AKI through transient G0/G1 cell cycle arrest.
• Transient protection from acute kidney injury
• CDK4/6 inhibitors are clinically approved
• Applicable to chemotherapy and surgically induced AKI
- CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury Am J Physiol Renal Physiol 2014 Feb 15;306(4):F379-88. doi: 10.1152/ajprenal.00475.2013. Epub 2013 Dec 11